BiondVax Pharmaceuticals Ltd. (TASE:BNDX) today announced that, on Friday, the safety committee of the Phase I/II clinical trial of the company's universal (or multi-strain) influenza vaccine has approved the continuation of the trial. The safety committee's approval was based on its review of the safety data from the 24 participants in the trial, which found that the vaccine was safe for use.
BiondVax will therefore continue the clinical trial on the basis of the current protocol, using a dose two times greater than the last dose in the trial so far. This will be the largest dosage under the trial protocol. The larger dosage will be injected in six participants, three of whom will receive the adjuvant active ingredient, and three who will not receive it.
On the basis of the safety results obtained in the stage of the clinical trial and with the permission of the safety committee that will review the results, BiondVax will expand the trial to 24 more participants. Some will receive the higher dosage with or without adjuvant, while others will be given a placebo.
BiondVax's share rose 10.7% by mid-afternoon to NIS 1.75.
Published by Globes [online], Israel business news - www.globes-online.com - on July 19, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009